We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Metformin Versus Insulin in Gestational Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01240785
Recruitment Status : Completed
First Posted : November 15, 2010
Results First Posted : November 24, 2014
Last Update Posted : November 24, 2014
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Gestational Diabetes
Interventions: Drug: metformin
Drug: insulin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Metformin Arm No text entered.
Insulin No text entered.

Participant Flow:   Overall Study
    Metformin Arm   Insulin
STARTED   111   110 
COMPLETED   110 [1]   107 
Lost to Follow-up                1                0 
Protocol Violation                0                3 
[1] 110 women completed in the metformin arm and 107 women completed in the insulin arm.

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Metformin metformin: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
Insulin insulin: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
Total Total of all reporting groups

Baseline Measures
   Metformin   Insulin   Total 
Overall Participants Analyzed 
[Units: Participants]
 110   107   217 
[Units: Years]
Mean (Standard Deviation)
 31.9  (5.0)   32.1  (5.4)   32.0  (4.6) 
[Units: Participants]
Female   110   107   217 
Male   0   0   0 
Region of Enrollment 
[Units: Participants]
Finland   110   107   217 

  Outcome Measures

1.  Primary:   Birth Weight Per Arm   [ Time Frame: delivery ]

2.  Secondary:   Pregnancy Induced Hypertension Per Arm   [ Time Frame: up to on the average 40 weeks of gestation ]

3.  Secondary:   Maternal Weight Gain Per Arm   [ Time Frame: up to on the average 40 weeks of gestation ]

4.  Secondary:   Pre-eclampsia Per Arm   [ Time Frame: up to on the average 40 weeks of gestation ]

5.  Secondary:   Mode of Delivery Per Arm   [ Time Frame: delivery ]

6.  Secondary:   Gestational Weeks at Delivery Per Arm   [ Time Frame: delivery ]

7.  Secondary:   Induction of Delivery Per Arm   [ Time Frame: delivery ]

8.  Secondary:   Shoulder Dystocia Per Arm   [ Time Frame: delivery ]

9.  Secondary:   Neonatal Hypoglycemia Per Arm   [ Time Frame: 0-24 h after delivery ]

10.  Secondary:   Neonatal Hyperbilirubinemia Per Arm   [ Time Frame: 0-3 days after delivery ]

11.  Secondary:   Apgar Score at 5 Min After Delivery Per Arm   [ Time Frame: 5 minutes after delivery ]

12.  Secondary:   Neonate Transfer to Intensive Care Unit Per Arm   [ Time Frame: 0-5 days after delivery ]

13.  Secondary:   Child Outcome at 2 Years Per Arm   [ Time Frame: 2 years after birth ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr Kristiina Tertti
Organization: Department of Obstetrics and Gynecology, Turku University Central Hospital
phone: +358 2 3130000
e-mail: kristiina.tertti@tyks.fi

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Tapani Rönnemaa, Turku University Hospital
ClinicalTrials.gov Identifier: NCT01240785     History of Changes
Other Study ID Numbers: 246/2005
First Submitted: November 3, 2010
First Posted: November 15, 2010
Results First Submitted: December 4, 2013
Results First Posted: November 24, 2014
Last Update Posted: November 24, 2014